Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity

European Journal of Pharmacology

Volumn 452, Issue 3, 2002, Pages 295-301

  Wallace, Melisa J ^a,b   Martin, Billy R ^a   DeLorenzo, Robert J ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anandamide; Cannabinoid; Cannabinoid CB1 receptor; Electroshock; Epilepsy; Maximal; O 1812; Seizure

Indexed keywords

(20 CYANO 16,16 DIMETYLDOCOSA 5,8,11,14 TETRAENOYL) 1' HYDROXY 2' PROPYLAMINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; O 1812; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ELECTRIC SHOCK; FISHER EXACT TEST; MALE; NONHUMAN; PRIORITY JOURNAL; SEIZURE THRESHOLD;

ANIMALS; ANTICONVULSANTS; ARACHIDONIC ACIDS; ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; MALE; MICE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SEIZURES;

EID: 0037064266     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02331-2     Document Type: Article

References (34)

1. 1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309(3):2001;197-201.
2. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 91:1996;1585-1614.
3. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209-1217.
4. Ameri A., Wilhelm A., Simmet T. Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br. J. Pharmacol. 126:1999;1831-1839.
5. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:2001;300-302.
6. Bayewitch M., Rhee M.H., Avidor-Reiss T., Breuer A., Mechoulam R., Vogel Z. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J. Biol. Chem. 271:1996;9902-9905.
7. Compton D.R., Martin B.R. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J. Pharmacol. Exp. Ther. 283:1997;1138-1143.
8. Costa B., Vailati S., Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav. Pharmacol. 10:1999;327-331.
9. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept. Channels. 1:1993;121-134.
10. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
11. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
12. Di Marzo V., Bisogno T., De Petrocellis L., Brandi I., Jefferson R.G., Winckler R.L., Davis J.B., Dasse O., Mahadevan A., Razdan R.K., Martin B.R. Highly selective CB (1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem. Biophys. Res. Commun. 281(2):2001;444-451.
13. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U. S. A. 92:1995;3376-3380.
14. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
15. Giang D.K., Cravatt B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2238-2242.
16. Hansen H.H., Schmid P.C., Bittigau P., Lastres-Becker I., Berrendero F., Manzanares J., Ikonomidou C., Schmid H.H., Fernandez-Ruiz J.J., Hansen H.S. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78(6):2001;1415-1427.
17. Hauser W.A., Hesdorffer D.C. Epilepsy: Frequency, Causes and Consequences. 1990;Demos, New York.
18. Herkenham M. Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res. Monogr. 112:1991;129-145.
19. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634.
20. Howlett A.C., Scott D.K., Wilken G.H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem. Pharmacol. 38:1989;3297-3304.
21. Karler R., Cely W., Turkanis S.A. Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids. Life Sci. 15:1974;931-947.
22. Leach M.J., Marden C.M., Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 27:1986;490-497.
23. 2+ sequestration/extrusion mechanisms following excitotoxic glutamate exposure. Brain Res. 894:2001;56-67.
24. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose effect experiments. J. Pharmacol. Exp. Ther. 99:1949;96-113.
25. Lothman E.W., Bertram E.H., Stringer J.L. Functional anatomy of hippocampal seizures. Prog. Neurobiol. 37:1991;1-82.
26. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U. S. A. 89:1992;3825-3829.
27. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5802-5807.
28. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334.
29. 2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
30. Sieradzan K.A., Fox S.H., Hill M., Dick J.P., Crossman A.R., Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 57:2001;2108-2111.
31. Swinyard E.A. Experimental Models of Epilepsy - A Manual for the Laboratory Worker. 1972;438 Raven Press, New York City.
32. Szallasi A., Di Marzo V. New perspectives on enigmatic vanilloid receptors. Trends Neurosci. 23:2000;491-497.
33. Van der Stelt M., Veldhuis W.B., Van Haaften G.W., Fezza F., Bisogno T., Bär P.R., Veldink G.A., Vliegenthart J.F., Di Marzo V., Nicolay K. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21(22):2001;8765-8771.
34. 1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 428:2001;51-57.